Therefore, in patients with diabetes and ASCVD, GLP-1 receptor agonists and/or SGLT2 inhibitors are recommended to lower the cardiovascular risk, regardless of glucose control, in addition to standard care such as antiplatelet, antihypertensive, or lipid-lowering therapy. The gene discussed is SLC5A2; the disease is diabetes mellitus.